ae30907a-a08a-44f3-b656-b0ba9729c8e7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.500
- CHOLESTEROL_HOMEOSTASIS+0.400
- APICAL_JUNCTION+0.300
- APICAL_SURFACE+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- MYOGENESIS+0.300
- COAGULATION+0.200
- DNA_REPAIR+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- ESTROGEN_RESPONSE_LATE+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.400
- IL2_STAT5_SIGNALING-0.300
- KRAS_SIGNALING_UP-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- COMPLEMENT-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3EH-01A-22R-A22K-07 | — | B | 0.785 |
| 2 | SRR12475125 | — | — | 0.757 |
| 3 | MNG965 | — | — | 0.754 |
| 4 | SRR8518172 | — | E | 0.753 |
| 5 | TCGA-A1-A0SE-01A-11R-A084-07 | — | A | 0.751 |
| 6 | 0177d00d-7d3f-43c8-8d0f-e6333e73efa4 | — | — | 0.746 |
| 7 | TCGA-S3-AA14-01A-11R-A41B-07 | — | A | 0.740 |
| 8 | SRR8613741 | — | F | 0.738 |
| 9 | c3b46d4b-4d9f-4d2d-bbca-c0dbd6901e56 | — | — | 0.736 |
| 10 | SRR11296875 | — | — | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |